See the latest National Genomic Test Directory
A central feature of the NHS Genomic Medicine Service (GMS) is the National Genomic Test Directory (Test Directory) which outlines the full range of genomic tests that are funded by the NHS in England. The Test Directory sets out which tests are available and the patients who are eligible to access a test.
NHS England and NHS Improvement held a public consultation on the approach to updating the Test Directory in Autumn 2020. The consultation documents and our response to the feedback received can be found on our consultation hub.
Our response to the consultation is also available below.
Updating the National Genomic Test Directory – the process
The Test Directory will be updated annually from 2021/22 following the structured, evidence-based process set out below. This will allow for a wide group of stakeholders to contribute to updating the Test Directory. For further information about the process, please see the guidance documentation.
Applications for amendments to the Test Directory must be submitted using the application forms available at the bottom of this page, noting the annual evaluation timescales below.
2021/22 update to the Test Directory
For the 2021/2022 update, NHS England and NHS Improvement implemented a bespoke application window. Applications to update the Test Directory for 2021/22 were accepted until 31 January 2021. The 2021/22 update to the Test Directory will be published in Summer 2021.
2022/23 update to the Test Directory
The 2022/23 update to the Test Directory will be published and implemented by April 2022. Applications submitted prior to 11.59pm on 1 August 2021* will be evaluated during this annual cycle and considered for inclusion in the 2022/23 update to the Test Directory.
*Please note: The deadline of 1 August 2021 for the receipt of applications for the 2022/23 update to the Test Directory has been extended to 11.59pm on 30 September 2021.
NHS GMS virtual gene panel content
NHS England and NHS Improvement will undertake a quarterly review and update of NHS GMS virtual gene panel content. Proposed amendments to the content of NHS GMS virtual gene panels should be submitted as evidence reviews via the Genomics England PanelApp platform.
For more information please see the guidance documentation.
Update to NHS GMS Virtual Gene Panels during 2020/21
A review of NHS GMS virtual gene panel content will take place during February – March 2021. Any evidence reviews relating to NHS GMS gene panel content submitted prior to 11.59pm 31 January 2021 will be reviewed during this update.
The quarterly reviews of NHS GMS virtual gene panel content will take place as per the below timescales*:
Date of review
Deadline for evidence reviews for inclusion in review
|June 2021||1 June 2021|
|September 2021||1 September 2021|
|December 2021||1 December 2021|
|March 2022||1 March 2022|
*Please note that following the 2021/22 update to the Test Directory the timescales for the 2022/23 update may be reviewed for suitability and effectiveness. Please check this page following the publication of the 2021/22 update to the Test Directory for confirmation of the timescales.
Fast track process
A fast track process for applications to amend the Test Directory is provided to support amendments that may be identified as requiring implementation more urgently than through the annual update to the Test Directory. Further information on this process and relevant documentation can be found in the documentation section below.
Fast track applications must be submitted to the Genomics Unit at firstname.lastname@example.org.
NHS England and NHS Improvement undertake ongoing horizon scanning to identify potential future changes to the Test Directory.
To support this horizon scanning, stakeholders can notify NHS England and NHS Improvement of activity which may result in a future change to the Test Directory via the notification form provided.
Please submit the form to the Genomics Unit at email@example.com.